EMA Recommends Extension of Therapeutic Indications for Ponatinib By Ogkologos - February 27, 2026 174 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Female Breast Cancer is Now the Most Commonly Diagnosed Cancer in... February 11, 2021 Efficacy and Safety of Trastuzumab and Pertuzumab in Combination with FLOT... June 21, 2022 ESMO Asia Congress 2022, 2-4 December 2022 November 17, 2022 Picking out the patterns: How scientists are finding cancer’s signatures in... June 15, 2022 Load more HOT NEWS Pembrolizumab Improves Survival in Advanced Triple-Negative Breast Cancer Breast Cancer Patient Is Accused of Having “Body Image Issues” After... Nanoparticle Trains Immune Cells to Attack Cancer Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas
